Itoco Inc. (ITMC)
USD 0.01
(177.78%)
USD 0.01
(177.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.86 Million USD | -2.67% |
| 2022 | -1.82 Million USD | -4691.17% |
| 2021 | -37.99 Thousand USD | 97.32% |
| 2020 | -1.41 Million USD | 52.27% |
| 2019 | -2.97 Million USD | -10.37% |
| 2018 | -2.69 Million USD | -55.57% |
| 2017 | -1.73 Million USD | -240.89% |
| 2016 | -507.77 Thousand USD | -28.94% |
| 2015 | -393.79 Thousand USD | 0.0% |
| 2013 | -2.26 USD | 0.0% |
| 2009 | -2.41 Million USD | -3660.82% |
| 2008 | -64.14 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -1.86 Million USD | -2.67% |
| 2023 Q3 | -239 Thousand USD | -2.64% |
| 2023 Q2 | -232.84 Thousand USD | 13.63% |
| 2023 Q4 | -1.12 Million USD | -371.77% |
| 2023 Q1 | -269.6 Thousand USD | 35.62% |
| 2022 FY | -1.82 Million USD | -4691.17% |
| 2022 Q1 | -159.98 Thousand USD | -153.75% |
| 2022 Q4 | -418.76 Thousand USD | 51.71% |
| 2022 Q3 | -867.12 Thousand USD | -131.15% |
| 2022 Q2 | -375.13 Thousand USD | -134.49% |
| 2021 Q4 | 297.63 Thousand USD | 202.52% |
| 2021 FY | -37.99 Thousand USD | 97.32% |
| 2021 Q1 | -300.83 Thousand USD | 0.0% |
| 2021 Q2 | -251.66 Thousand USD | 16.34% |
| 2021 Q3 | -290.31 Thousand USD | -15.36% |
| 2020 FY | -1.41 Million USD | 52.27% |
| 2019 FY | -2.97 Million USD | -10.37% |
| 2018 FY | -2.69 Million USD | -55.57% |
| 2017 FY | -1.73 Million USD | -240.89% |
| 2016 FY | -507.77 Thousand USD | -28.94% |
| 2015 FY | -393.79 Thousand USD | 0.0% |
| 2013 FY | -2.26 USD | 0.0% |
| 2010 Q3 | 113.11 Thousand USD | 119.54% |
| 2010 Q2 | -578.82 Thousand USD | -233.94% |
| 2010 Q1 | -173.33 Thousand USD | 92.7% |
| 2009 Q1 | -15.66 Thousand USD | -54.37% |
| 2009 Q3 | -6723.00 USD | 57.39% |
| 2009 Q4 | -2.37 Million USD | -35213.12% |
| 2009 Q2 | -15.77 Thousand USD | -0.75% |
| 2009 FY | -2.41 Million USD | -3660.82% |
| 2008 Q4 | -10.14 Thousand USD | 1.2% |
| 2008 Q1 | -34.37 Thousand USD | 0.0% |
| 2008 Q3 | -10.26 Thousand USD | -9.77% |
| 2008 Q2 | -9354.00 USD | 72.79% |
| 2008 FY | -64.14 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -39.954% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 73.234% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.528% |
| Nascent Biotech, Inc. | -2.08 Million USD | 10.475% |
| Rebus Holdings, Inc. | -1.02 Million USD | -83.235% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.87% |
| Qrons Inc. | -789.34 Thousand USD | -136.777% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -195.537% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.014% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -349.841% |
| Skye Bioscience, Inc. | -37.64 Million USD | 95.035% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.507% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 71.579% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -583.607% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.648% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 35.382% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -2.662% |
| Mesoblast Limited | -87.95 Million USD | 97.875% |
| Marizyme, Inc. | -65.34 Million USD | 97.14% |
| Genus plc | 7.9 Million USD | 123.658% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 82.84% |
| Pharming Group N.V. | -10.54 Million USD | 82.281% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 13.864% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 49.626% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 78.867% |
| ContraFect Corporation | -65.15 Million USD | 97.131% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 61.748% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -8.194% |
| IMV Inc. | -36.48 Million USD | 94.877% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 76.811% |
| MultiCell Technologies, Inc. | -380.07 USD | -491650.204% |
| ONE Bio Corp. | 8.67 Million USD | 121.541% |
| Accustem Sciences Inc. | -3.74 Million USD | 50.112% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 96.384% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -47.498% |
| Q BioMed Inc. | -2.05 Million USD | 8.923% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 49.933% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 21.499% |
| Biomind Labs Inc. | -1.21 Million USD | -53.913% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.871% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 39.744% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 76.351% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 4.117% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -12379.935% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 88.224% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 67.872% |
| GB Sciences, Inc. | -1.36 Million USD | -37.257% |
| Alpha Cognition Inc. | -13.77 Million USD | 86.43% |
| HST Global, Inc. | -146.21 Thousand USD | -1178.295% |
| CSL Limited | 2.64 Billion USD | 100.071% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -6.509% |
| Halberd Corporation | -79.67 Thousand USD | -2245.744% |
| Enzolytics Inc. | -2.17 Million USD | 14.142% |
| Agentix Corp. | -1.37 Million USD | -36.005% |
| Resverlogix Corp. | -3.61 Million USD | 48.227% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 41.068% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.367% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2007.138% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 126.991% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 52.958% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 38.238% |
| AVAX Technologies, Inc. | -6.41 Million USD | 70.859% |
| Zenith Capital Corp. | -10.59 Million USD | 82.361% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.042% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -7941.455% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 54.92% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2992.283% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 6.789% |
| Kadimastem Ltd | -3.3 Million USD | 43.49% |
| Helix BioMedix, Inc. | -1.05 Million USD | -76.979% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 51.061% |
| BioStem Technologies, Inc. | -8.48 Million USD | 77.968% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -323.454% |
| LadRx Corporation | 400.44 Thousand USD | 566.732% |
| Cell Source, Inc. | -5.32 Million USD | 64.877% |
| Regen BioPharma, Inc. | 1.02 Million USD | 282.607% |
| Regen BioPharma, Inc. | 1.02 Million USD | 282.607% |
| NovAccess Global Inc. | -4.76 Million USD | 60.811% |
| Affymax, Inc. | -14.42 Million USD | 87.042% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 57.93% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -11.983% |
| Mobile Lads Corp. | -2.26 Million USD | 17.421% |
| CytoDyn Inc. | -49.84 Million USD | 96.25% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2264.829% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -719.278% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -98.506% |
| SYBLEU INC | -180.3 Thousand USD | -936.58% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -15.89% |
| International Stem Cell Corporation | -131 Thousand USD | -1326.714% |
| Bioxytran, Inc. | -4.28 Million USD | 56.332% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3343.756% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 26.134% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 96.112% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 11.59% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -139.343% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 41.004% |
| Neutra Corp. | -233.46 Thousand USD | -700.546% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 90.789% |
| PureTech Health plc | -65.69 Million USD | 97.155% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 91.212% |
| IXICO plc | -1.17 Million USD | -58.658% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 81.173% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.728% |
| CSL Limited | 2.64 Billion USD | 100.071% |
| Cellectis S.A. | -103.17 Million USD | 98.188% |